ANGPTL2 and prostate carcinoma: Immunohistochemical staining revealed that ANGPTL2 was expressed at higher levels in human prostate cancer tissues after androgen ablation therapy than in human prostate cancer tissues without androgen ablation therapy (Fig. 8A and B).